Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR. Methods: We retrospectively analyzed the data of peo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Infectious Disease Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7449/15/6/69 |
| _version_ | 1797380775942815744 |
|---|---|
| author | Anna Gidari Sara Benedetti Sara Tordi Anastasia Zoffoli Debora Altobelli Elisabetta Schiaroli Giuseppe Vittorio De Socio Daniela Francisci |
| author_facet | Anna Gidari Sara Benedetti Sara Tordi Anastasia Zoffoli Debora Altobelli Elisabetta Schiaroli Giuseppe Vittorio De Socio Daniela Francisci |
| author_sort | Anna Gidari |
| collection | DOAJ |
| description | Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR. Methods: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023. Results: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2–2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count. Conclusions: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART. |
| first_indexed | 2024-03-08T20:42:51Z |
| format | Article |
| id | doaj.art-85a7cb2e3aa845cc92ef9b7ba32f0f7d |
| institution | Directory Open Access Journal |
| issn | 2036-7449 |
| language | English |
| last_indexed | 2024-03-08T20:42:51Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Infectious Disease Reports |
| spelling | doaj.art-85a7cb2e3aa845cc92ef9b7ba32f0f7d2023-12-22T14:13:04ZengMDPI AGInfectious Disease Reports2036-74492023-12-0115676677710.3390/idr15060069Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)Anna Gidari0Sara Benedetti1Sara Tordi2Anastasia Zoffoli3Debora Altobelli4Elisabetta Schiaroli5Giuseppe Vittorio De Socio6Daniela Francisci7Department of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, ItalyBackground: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR. Methods: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023. Results: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2–2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count. Conclusions: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.https://www.mdpi.com/2036-7449/15/6/69HIVbictegravirintegrase inhibitorsreal-lifeantiretroviral |
| spellingShingle | Anna Gidari Sara Benedetti Sara Tordi Anastasia Zoffoli Debora Altobelli Elisabetta Schiaroli Giuseppe Vittorio De Socio Daniela Francisci Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) Infectious Disease Reports HIV bictegravir integrase inhibitors real-life antiretroviral |
| title | Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) |
| title_full | Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) |
| title_fullStr | Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) |
| title_full_unstemmed | Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) |
| title_short | Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) |
| title_sort | bictegravir tenofovir alafenamide emtricitabine a real life experience in people living with hiv plwh |
| topic | HIV bictegravir integrase inhibitors real-life antiretroviral |
| url | https://www.mdpi.com/2036-7449/15/6/69 |
| work_keys_str_mv | AT annagidari bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT sarabenedetti bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT saratordi bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT anastasiazoffoli bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT deboraaltobelli bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT elisabettaschiaroli bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT giuseppevittoriodesocio bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh AT danielafrancisci bictegravirtenofoviralafenamideemtricitabineareallifeexperienceinpeoplelivingwithhivplwh |